WEKO3
アイテム
{"_buckets": {"deposit": "b17033d5-397d-4157-92a3-1a22b0fb5bef"}, "_deposit": {"created_by": 1, "id": "66329", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "66329"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00066329", "sets": ["29"]}, "author_link": ["652625", "652627", "652628", "652629", "652630", "652632", "652631", "652623", "652626", "652624", "652622", "652621"], "item_10005_date_7": {"attribute_name": "発表年月日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2017-05-13", "subitem_date_issued_type": "Issued"}]}, "item_10005_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Purpose: To determine the prognostic factors for biochemical recurrence (BR) and mortality in patients with high-risk localized prostate cancer after carbon-ion radiotherapy (CIRT) combined with long-term androgen deprivation therapy (LTADT).\nMethods and Materials: A total of 1247 patients were enrolled in three phase II clinical trials of fixed-dose CIRT between 2000 and 2013. Excluding T4 disease, 614 patients received CIRT combined with LTADT for high- or very-high-risk disease, according to the National Comprehensive Cancer Network (NCCN) classification system. \nResults: Median follow-up time was 78.7 months, and 5-year rates of BR-free, prostate cancer-specific survival, and overall survival were 90.4% (95% confidence interval [CI]: 87.6 - 92.7), 98.5% (95% CI: 97.2 - 99.2), and 94.7% (95% CI: 92.8 - 96.5), respectively. T3a/b disease, Gleason score (GS) 9-10, percentage of positive biopsy cores (PPCs) \u003e 75%, and age \u003e 75 years had a significant impact on BR. Moreover, patients with T3b disease, GS 9-10, and PPCs \u003e 75% had significantly higher prostate cancer-specific mortality (p = 0.007, p = 0.009, and p = 0.015, respectively) and overall mortality (p = 0.035, p = 0.025, and p \u003c 0.001, respectively), on multivariate analyses.\nConclusions: Prognostic factors for BR and mortality were identified. Patients with T3b disease, GS 9-10, and PPCs \u003e 75% should be considered to have very-high-risk disease requiring a new treatment strategy.", "subitem_description_type": "Abstract"}]}, "item_10005_description_6": {"attribute_name": "会議概要(会議名, 開催地, 会期, 主催者等)", "attribute_value_mlt": [{"subitem_description": "the 56th Annual Conference of the Particle Therapy Co-operative Group (PTCOG56) ", "subitem_description_type": "Other"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Kasuya, Goro"}], "nameIdentifiers": [{"nameIdentifier": "652621", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ishikawa, Hitoshi"}], "nameIdentifiers": [{"nameIdentifier": "652622", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsuji, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "652623", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Makishima, Hirokazu"}], "nameIdentifiers": [{"nameIdentifier": "652624", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nomiya, Takuma"}], "nameIdentifiers": [{"nameIdentifier": "652625", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kamada, Tadashi"}], "nameIdentifiers": [{"nameIdentifier": "652626", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "粕谷 吾朗", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "652627", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "石川 仁", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "652628", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "辻 比呂志", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "652629", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "牧島 弘和", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "652630", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "野宮 琢磨", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "652631", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "鎌田 正", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "652632", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference object", "resourceuri": "http://purl.org/coar/resource_type/c_c94f"}]}, "item_title": "Prognostic Factors in High-Risk Prostate Cancer after Carbon-Ion Radiotherapy Combined with Long-Term Androgen Deprivation Therapy", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Prognostic Factors in High-Risk Prostate Cancer after Carbon-Ion Radiotherapy Combined with Long-Term Androgen Deprivation Therapy"}]}, "item_type_id": "10005", "owner": "1", "path": ["29"], "permalink_uri": "https://repo.qst.go.jp/records/66329", "pubdate": {"attribute_name": "公開日", "attribute_value": "2017-05-23"}, "publish_date": "2017-05-23", "publish_status": "0", "recid": "66329", "relation": {}, "relation_version_is_last": true, "title": ["Prognostic Factors in High-Risk Prostate Cancer after Carbon-Ion Radiotherapy Combined with Long-Term Androgen Deprivation Therapy"], "weko_shared_id": -1}
Prognostic Factors in High-Risk Prostate Cancer after Carbon-Ion Radiotherapy Combined with Long-Term Androgen Deprivation Therapy
https://repo.qst.go.jp/records/66329
https://repo.qst.go.jp/records/6632913d78f84-f2a5-4566-8efd-b7209ee298a7
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2017-05-23 | |||||
タイトル | ||||||
タイトル | Prognostic Factors in High-Risk Prostate Cancer after Carbon-Ion Radiotherapy Combined with Long-Term Androgen Deprivation Therapy | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Kasuya, Goro
× Kasuya, Goro× Ishikawa, Hitoshi× Tsuji, Hiroshi× Makishima, Hirokazu× Nomiya, Takuma× Kamada, Tadashi× 粕谷 吾朗× 石川 仁× 辻 比呂志× 牧島 弘和× 野宮 琢磨× 鎌田 正 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Purpose: To determine the prognostic factors for biochemical recurrence (BR) and mortality in patients with high-risk localized prostate cancer after carbon-ion radiotherapy (CIRT) combined with long-term androgen deprivation therapy (LTADT). Methods and Materials: A total of 1247 patients were enrolled in three phase II clinical trials of fixed-dose CIRT between 2000 and 2013. Excluding T4 disease, 614 patients received CIRT combined with LTADT for high- or very-high-risk disease, according to the National Comprehensive Cancer Network (NCCN) classification system. Results: Median follow-up time was 78.7 months, and 5-year rates of BR-free, prostate cancer-specific survival, and overall survival were 90.4% (95% confidence interval [CI]: 87.6 - 92.7), 98.5% (95% CI: 97.2 - 99.2), and 94.7% (95% CI: 92.8 - 96.5), respectively. T3a/b disease, Gleason score (GS) 9-10, percentage of positive biopsy cores (PPCs) > 75%, and age > 75 years had a significant impact on BR. Moreover, patients with T3b disease, GS 9-10, and PPCs > 75% had significantly higher prostate cancer-specific mortality (p = 0.007, p = 0.009, and p = 0.015, respectively) and overall mortality (p = 0.035, p = 0.025, and p < 0.001, respectively), on multivariate analyses. Conclusions: Prognostic factors for BR and mortality were identified. Patients with T3b disease, GS 9-10, and PPCs > 75% should be considered to have very-high-risk disease requiring a new treatment strategy. |
|||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | the 56th Annual Conference of the Particle Therapy Co-operative Group (PTCOG56) | |||||
発表年月日 | ||||||
日付 | 2017-05-13 | |||||
日付タイプ | Issued |